A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Clinical trial NCT07189065 · RECRUITING
Trial details
- NCT number
- NCT07189065
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-27
- Primary completion
- 2027-12-31
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.